Loading
A phase 3 trial of Petosemtamab, Cetuximab, FOLFIRI in colorectal cancer, run by Genmab, now recruiting.
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1) is a phase 3 interventional study registered as NCT07702032 by Genmab, with 960 participants planned, started 2026-08-11 and due to reach its primary completion in 2029-07. Interventions recorded: Petosemtamab, Cetuximab, FOLFIRI, mFOLFOX6. Conditions listed: Left-sided Colorectal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Petosemtamab, Genmab, FOLFIRI (5-FU, leucovorin, irinotecan), Bispecific antibodies.
Shares Petosemtamab, Genmab, Cetuximab, Bispecific antibodies.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, FOLFOX (5-FU, leucovorin, oxaliplatin), Platinum agents.
Shares Petosemtamab, Genmab, Bispecific antibodies.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Platinum agents, Cytotoxic chemotherapy.
Shares Cetuximab, FOLFOX (5-FU, leucovorin, oxaliplatin), Platinum agents, Monoclonal antibodies.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, FOLFOX (5-FU, leucovorin, oxaliplatin), Platinum agents.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, Monoclonal antibodies, Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/